Study of treatments for advanced prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This study looks back at the experiences of men with prostate cancer that has spread to other parts of the body. It aims to learn which treatments—such as hormone therapy combined with other drugs, or a radioactive therapy—work best for different types of advanced prostate cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be over 18 years old.
- Your prostate cancer must be confirmed by a biopsy (tissue sample).
- Your cancer must have spread to other parts of the body (metastatic).
- You may have been treated with one of several combination therapies listed in the study (e.g., hormone therapy plus a targeted drug).
- If you received a special radioactive drug (Lutetium-177-PSMA), it must be for cancer that is no longer responding to hormone therapy.
- If you have an HRD gene change, you may have taken a PARP inhibitor drug (e.g., olaparib, niraparib, or talazoparib) in a specific combination.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at combining hormone therapy with either chemotherapy (docetaxel), a targeted pill (like abiraterone or enzalutamide), or radiation to the prostate tumor for men whose prostate cancer has spread but is still sensitive to hormones. The goal is to see which approach works best for controlling the cancer.
This trial tests whether a combination of three new drugs (SHR3680, HS-20093, and SHR2554) can help slow or stop prostate cancer growth. It is for men who are already on hormone therapy and whose PSA level is still rising.
This trial tests a targeted radiation drug (Lu177-PSMA) combined with procedures that treat liver tumors directly (like ablation or radiation). It is for men with prostate cancer that has spread to the liver and is no longer responding to hormone therapy. The goal is to see if this combination works better together.
This study tests different ways of giving hormone therapy to find the right dose for men with prostate cancer that has spread. It aims to help manage the disease while limiting side effects.
This study tests whether adding a type of high-precision radiation (MDRT) to standard hormone therapy works better for men with prostate cancer that has spread to just a few places. It is for patients who are newly diagnosed and on long-term hormone therapy.
This trial tests two new drugs (QLC5508 and QLH12016) alone or together with other treatments for prostate cancer that has spread to other parts of the body. It may be an option if standard treatments have stopped working or caused side effects.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.